Skip to content

Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin

Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00414362
Enrollment
1000
Registered
2006-12-21
Start date
2007-02-28
Completion date
2017-06-30
Last updated
2018-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacteremia, Fluoroquinolone, Urinary Tract Infection

Keywords

Bacteremia, Urinary Tract Infections, Fluoroquinolone

Brief summary

The information collected will optimize the management of patients with urinary tract infections with secondary bacteremia, primarily with gram negative bacteria especially Escherichia coli. The current IDSA guideline endorses the use of fluoroquinolones and trimethoprim-sulfamethoxazole as the first line agents. However, over use of this empiric regimen could result in in appropriate treatment of bacteremia.

Detailed description

The following information will be collected: age, sex, occupation, hospital location at the time of positive culture (ER, medical ward, ICU etc), prior hospitalization, receipt of outpatient dialysis, home care or other regular medical care (eg, outpatient chemotherapy), presence of invasive devices, receipt of antibiotics, including their type and whether they were adequate for the resistance profile of the organism, prior positive microbiologic cultures, time and location of positive cultures, underlying diseases and severity of illness, presence of urinary or intravascular devices, recent immunomodulative therapies or radiation therapy, physical exam findings, laboratory and radiographical data, antimicrobial usage within 30 days of onset of the infection, microbiological data and resistance patterns, choice of antibiotics once organism identified, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome,gender, height, weight, ethnicity, and past medical history. We will collect information retrospectively.

Interventions

None listed

Sponsors

Japan Health Sciences Foundation
CollaboratorUNKNOWN
University of Pittsburgh
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Clinical information is collected by chart review of case and control patients. A case patient is defined as follows: * One or more blood cultures are positive for Gram-negative bacteria. * The same organism is recovered in urine culture within a 48-hour period. * The organism is ciprofloxacin resistant. * A control patient is defined as follows: * One or more blood cultures are positive for Gram-negative bacteria. * The same organism is recovered in urine culture within a 48-hour period. * The organism is ciprofloxacin susceptible.

Exclusion criteria

* negative culture

Design outcomes

Primary

MeasureTime frameDescription
dead or aliveend of studyhealth status

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026